Proton Pump Inhibitors Market: Omeprazole is estimated to gain higher share during the forecast period

Proton pump inhibitors are a group of medicines that reduces the gastric acid secretion in the linings of the stomach. They block the enzyme process in the gastric system that actively transports gastric acid from parietal cells to the gastrointestinal lumen in the form of hydrogen–potassium adenosine triphosphate (proton pump). Proton pump inhibitors are used to relieve the symptoms of gastro-esophageal reflux diseases (GERD), peptic ulcers, dyspepsia, gastritis, and other gastrointestinal disorders. The medicines are administered orally, and they are available in the form of capsules and tablets. Proton pump inhibitors are among the most widely used medications, due to fewer side effects.

Request Brochure of Report –  https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=19169

Increasing acceptance of novel drug delivery systems and rising prevalence of peptic ulcer and other gastro-intestinal disorders are driving the proton pump inhibitors market considerably. Consumers in isolated regions tend to prefer the common antacids to deal with ulcer & gastro-intestinal disorders, which restrains the proton pump inhibitors market. Also, the increasing use of generic drugs in the proton pump inhibitors market can hamper the growth of the market. Increasing consumer acceptance of novel drug delivery systems and launching of new products is always an opportunity for the proton pump inhibitors market.

The proton pump inhibitors market can be segmented according to drug types. They are Omeprazole, Rabeprazole, Pantoprazole, Lansoprazole, Dexlansoprazole, Esomeprazole, and Others. Esomeprazole is the most widely prescribed drug for gastric ulcer in the proton pump inhibitors market. The segment dominated the proton pump inhibitors market in 2015 attributed to its potency, efficacy, and its wide distribution in the market. Dexlansoprazole & Rabeprazole were the second most widely prescribed medication types after Esomeprazole in 2015. Omeprazole is estimated to gain higher share during the forecast period, which is attributed to its availability in generic and over-the-counter form, and its cost-effectiveness. The patent license of drug Nexium (Esomeprazole) expired in the year 2015, which is the major reason for the likely domination of Omeprazole & Lansoprazole in the proton pump inhibitors market during the forecast period.

Request for Analysis of COVID-19 Impact on Proton Pump Inhibitors Market –  https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=19169

Overall, the market share of non-generic drugs has declined while the value of the generic drug market is expected to rise which can propel the proton pump inhibitor market. Continued usage of generic drugs of the Omeprazole segment is expected to raise the market share, which can surpass Nexium drug segment during the forecast period.

Geographically, the proton pump inhibitors market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America had the dominant market share in 2015, which is attributed to increase in prevalence of gastrointestinal disorders in the region and consistent launch of new products. However, the Asia Pacific market is estimated to grow at a higher CAGR by 2016- 2024. The Asia Pacific market is flooded with many gastrointestinal drug products and there is a large patient pool with gastro intestinal problems. This can create a need for curative drugs and this is anticipated to drive the proton pump inhibitors market in the region remarkably.

Pre Book Proton Pump Inhibitors Market Report at –  https://www.transparencymarketresearch.com/checkout.php?rep_id=19169&ltype=S

The major players in the proton pump Inhibitors market are AstraZeneca, Takeda Pharmaceuticals, Wyeth Pharmaceuticals, Eisai Pharmaceuticals India Pvt. Ltd., Teva Pharmaceuticals, Cadila Pharmaceuticals, Pfizer, Eli Lilly and Company, and Janssen Global Services, LLC. Consistent launching of new products is the strategy followed by key players to deal with the competition in the proton pump inhibitors market.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/

Back to news